SymbioCellTech recieves FDA approval to conduct pilot studies in pet dogs

Based on the strength of its Investigational New Animal Drug (INAD) application, SymbioCellTech (SCT) received FDA approval to begin a pilot study to test the safety and efficacy of its Neo-Islet therapy in insulin-dependent diabetic pet dogs. The trials are expected to begin at Washington State University in Pullman, WA and at the Veterinary Specialty Hospital in San Diego, CA in Q1 of 2017.